Developing blood tests for predicting complications in stem cell transplantation
Precision Medicine for Stem Cell Transplantation
This study is testing new blood tests to see if they can help predict complications like graft-versus-host disease and leukemia relapse in patients receiving stem cell transplants.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 300 (estimated) |
| Sex | All |
| Sponsor | University of Manchester Academic / other |
| Locations | 3 sites (Manchester and 2 other locations) |
| Trial ID | NCT05567289 on ClinicalTrials.gov |
What this trial studies
This observational study focuses on patients undergoing allogeneic haematopoietic stem cell transplantation (HSCT) to develop new blood tests that can predict the onset of acute graft-versus-host disease (aGvHD) and leukemia relapse. By collecting and analyzing blood samples from 300 transplant recipients at various stages of their treatment, the study aims to identify biomarkers that can help personalize prophylaxis and early interventions. The research will also create a valuable resource of clinically annotated samples for future studies in the transplant research community.
Who should consider this trial
Good fit: Ideal candidates include any recipient of allogeneic haematopoietic stem cell transplantation, including children and infants.
Not a fit: Patients who have received autologous stem cell transplants or weigh less than 5kg will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved management of complications in stem cell transplantation, enhancing patient outcomes.
How similar studies have performed: Other studies have shown promise in developing predictive biomarkers for complications in stem cell transplantation, making this approach both relevant and potentially impactful.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Any recipient of allogeneic haematopoietic stem cell transplantation (HSCT) * Children/infants may participate, there is no age restriction * Patients participating in other clinical trials remain eligible Exclusion Criteria: * Weight \<5kg * Recipients of autologous stem cell transplants
Where this trial is running
Manchester and 2 other locations
- Manchester Royal Infirmary — Manchester, United Kingdom (Recruiting)
- Royal Manchester Children's Hospital — Manchester, United Kingdom (Recruiting)
- The Christie NHS Foundation Trust — Manchester, United Kingdom (Recruiting)
Study contacts
- Principal investigator: Mark Williams — CRUK Manchester Institute
- Study coordinator: Mark Williams
- Email: mark.williams-4@cruk.manchester.ac.uk
- Phone: +441613063240
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.